NewsBenzingaCraig-Hallum mantiene su recomendación de compra sobre Myriad Genetics y eleva el precio objetivo a 8 dólares. Craig-Hallum mantiene su recomendación de compra sobre Myriad Genetics y eleva el precio objetivo a 8 dólares. Benzinga 2026.10.02 17:53 (GMT+0) Open on Benzinga Other news NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal Archer Aviation Says Court Dismisses Some Of Joby's Trade Secret And Contract Claims, Lets Others Proceed; Archer's Counterclaims Against Joby Dismissed Jefferies Maintains Buy on Huntsman, Lowers Price Target to $11 Silynxcom Signs ATM Sales Agreement With Think Equity; Terms Undisclosed Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance Here's How Much $100 Invested In Affiliated Managers Group 5 Years Ago Would Be Worth Today
Archer Aviation Says Court Dismisses Some Of Joby's Trade Secret And Contract Claims, Lets Others Proceed; Archer's Counterclaims Against Joby Dismissed
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
